⭐ Stool Hb Quantitative Test: A Complete Guide to Early Detection of Colorectal Cancer (2026)
⭐ Stool Hb Quantitative Test: A Complete Guide to Early Detection of Colorectal Cancer
What Is the Stool Hb Quantitative Test?
The Stool Hb Quantitative Test, also known as Fecal Hemoglobin Quantification or qFIT, is a highly sensitive method for detecting hidden blood in stool.
Colorectal cancer often produces microscopic bleeding long before symptoms appear, making qFIT a critical tool for early detection.
Unlike older guaiac-based tests, qFIT provides numerical values, offers high specificity for human hemoglobin, and does not require dietary restrictions.
1. Purpose of the Stool Hb Quantitative Test
The test measures tiny amounts of human hemoglobin (Hb) in stool to identify bleeding originating from the colon.
Primary Purposes
- Early detection of colorectal cancer
- Identification of advanced adenomas or bleeding polyps
- Evaluation of inflammatory bowel disease (IBD) such as Crohn’s disease or ulcerative colitis
- Assessment of unexplained symptoms (weight loss, anemia, abdominal discomfort)
- Routine screening for adults aged 50+ or high-risk groups
Because it detects very small amounts of bleeding, qFIT has become the standard method in many national colorectal cancer screening programs.
2. Required Specimen
✔ Specimen type
- Single stool sample
✔ Patient preparation
- No dietary restrictions
- No medication restrictions (NSAIDs may increase minor bleeding but do not invalidate results)
✔ Collection precautions
- Avoid contamination with urine or toilet water
- Avoid testing during menstruation
- Anal bleeding from constipation may cause false positives
✔ Storage
- Store at 2–8°C
- Submit to the laboratory within 24 hours for optimal accuracy
3. Test Method: Turbidimetric Immunoassay (TIA)
Most laboratories use the Quantitative Fecal Immunochemical Test (qFIT), based on turbidimetric immunoassay.
How it works
- Antibodies target human hemoglobin specifically.
- Antigen–antibody complexes form.
- The analyzer measures turbidity (cloudiness).
- Higher turbidity = higher stool hemoglobin concentration.
Advantages
- Detects human hemoglobin only → no dietary interference
- Highly sensitive for lower GI bleeding
- Provides numeric values for risk stratification
- Better performance than qualitative FOBT
4. Reference Range
Common reference threshold:
- Negative: < 50 ng/mL
Cut-off values may vary slightly by laboratory or national screening program.
5. Clinical Significance & Related Conditions
A positive qFIT indicates detectable bleeding from the lower gastrointestinal tract.
Possible causes of a positive result
- Colorectal cancer
- Advanced adenomas or polyps
- Inflammatory bowel disease (UC / Crohn’s disease)
- Diverticulitis
- Hemorrhoids
- Colonic ulcer or mucosal erosion
Risk correlation
Higher Hb concentration in stool → greater likelihood of significant colorectal pathology.
Is a negative result fully reassuring?
Not always.
Bleeding may be intermittent, and early lesions may produce minimal blood.
Patients with symptoms must still undergo colonoscopy regardless of qFIT results.
6. Interpretation & Key Precautions
1) Hemorrhoids may cause false-positive results
Bleeding from the anal canal, not the colon, can increase stool Hb levels.
2) Upper GI bleeding may be missed
Stomach or small intestine bleeding is often digested before reaching the colon → false-negative possible.
3) Constipation-related fissures
Straining can cause minor bleeding → mild positive results.
4) One test is not enough for high-risk patients
Annual testing is recommended for:
- Age ≥ 50
- Family history of colorectal cancer
- Previous polyps
- Chronic GI symptoms
Conclusion
The Stool Hb Quantitative Test (qFIT) is one of the most effective, non-invasive tools for the early detection of colorectal cancer.
Its accuracy, convenience, and high sensitivity make it a valuable screening method—especially for individuals without symptoms but at increased risk.
Regular screening, combined with timely colonoscopy when indicated, remains the best strategy for preventing advanced colorectal disease.
References
- Young GP et al. Fecal immunochemical tests for colorectal cancer screening. Clin Gastroenterol Hepatol. 2021.
- Halloran S et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Endoscopy. 2012.
- Korea Health Promotion Institute. National Colorectal Cancer Screening Guidelines.
- Levin B et al. Screening and surveillance for early detection of colorectal cancer. CA Cancer J Clin.
- Rex DK. FIT for screening: a primer. Gastroenterology Clinics. 2020.